Picture of Sun Pharmaceutical Industries logo

SUNPHARMA — Sun Pharmaceutical Industries News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

India's Sun Pharma hits record high after Brazil's approval for semaglutide

BUZZ-India's Sun Pharma hits record high after Brazil's approval for semaglutide 

** Drug maker Sun Pharma's shares SUN.NS rise as much as 1.35% to a record high of 2016.80 rupees apiece

** SUN receives approval from Brazil's health regulator, ANVISA, to manufacture and market its semaglutide injection in Brazil

** Semaglutide is used in the treatment of adults with inadequately controlled type 2 diabetes, alongside diet and exercise

** Size of semaglutide injectable market in Brazil is approximately $413 million as of June 2026, according to IQVIA

** SUN says it plans to launch the product in the next few days in partnership with Brazilian firm Hypera Pharma

** "Approval marks an important step in strengthening diabetes portfolio in Brazil," says Digvijay Singh, regional head of Brazil and Latin America at SUN

** SUN shares are up 17.1% in 2026 so far, mirroring the pharma index's .NIPHARM 16.4% rise, according to exchange data


(Reporting by Bharath Rajeswaran in Bengaluru)

((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))

Recent news on Sun Pharmaceutical Industries

See all news